GeNO LLC is a biopharmaceutical company developing next-generation inhaled nitric oxide (NO) products designed to address unmet medical needs in patients with pulmonary and cardiac diseases. The company's proprietary GeNOsyl® drug delivery technology comprises a single-use drug cassette paired with either a portable console or wearable controller,... enabling safe and effective NO delivery across both acute hospital settings and longer-term outpatient applications. GeNO's lead product, GeNOsyl Acute DS, is engineered to deliver a constant intra-breath concentration of therapeutic NO to ventilated patients in hospital environments while also supporting administration via nasal cannula or face mask, with a design emphasis on simplicity and intuitive clinical use. The company was founded on a distinctive scientific insight: conventional NO delivery methods based on dilution of concentrated nitric oxide inevitably produce significant co-delivery of nitrogen dioxide (NO2) due to the non-linear kinetics of NO-oxygen reactions. GeNO's proprietary chemistry addresses this limitation by starting with NO2 and chemically removing one oxygen atom to generate nitric oxide rapidly and quantitatively, thereby minimizing the problematic dilution step and improving safety and efficacy profiles compared to existing NO delivery systems. This chemistry-first approach, developed by founder Dr. David Fine, who brings four decades of expertise in NO and NO2 chemistry, represents a meaningful advancement in inhaled nitric oxide therapeutics. GeNO currently maintains two active Investigational New Drug Applications (INDs) utilizing its nitric oxide delivery system, with clinical studies exploring NO as a diagnostic agent for right heart catheterization in patients with pulmonary arterial hypertension and other therapeutic indications. The company's differentiated technology platform, combined with its focus on user-friendly clinical solutions and rigorous chemical precision, positions GeNO to compete effectively in the inhaled ... Read More

GeNO

Q: What industry does GeNO belong to?

GeNO is in the industry of: Manufacturing , Pharmaceuticals , Business Services

Manufacturing · Georgia, United States · 51-200 Employees

View Company Info for Free

Overview

Headquarters

387 Technology Cir NW Ste 125, Atlanta, ...

Phone Number

(678) 862-7729

Website

www.genollc.com

Revenue

$18 Million

Industry

Manufacturing

Pharmaceuticals

Business Services

Research & Development

Medical Devices & Equipment

ZI Rank: 1

Signal Type

Dec

Jan

Feb

Mar

Apr

May

ZI Rank

About GeNO

GeNO LLC is a biopharmaceutical company developing next-generation inhaled nitric oxide (NO) products designed to address unmet medical needs in patients with pulmonary and cardiac diseases. The company's proprietary GeNOsyl® drug delivery technology comprises a single-use drug cassette paired with either a portable console or wearable controller, enabling safe and effective NO delivery across both acute hospital settings and longer-term outpatient applications. GeNO's lead product, GeNOsyl Acute DS, is engineered to deliver a constant intra-breath concentration of therapeutic NO to ventilated patients in hospital environments while also supporting administration via nasal cannula or face mask, with a design emphasis on simplicity and intuitive clinical use. The company was founded on a distinctive scientific insight: conventional NO delivery methods based on dilution of concentrated nitric oxide inevitably produce significant co-delivery of nitrogen dioxide (NO2) due to the non-linearRead more

Is this data correct?

View contact profiles from GeNO

Popular SearchesGeno LLCGeNOGeno 2 LLCGeno Freeman and Company LLCSIC Code 28,283NAICS Code 32,325Show more

GeNO Org Chart

Phone

Johnathan Crocker

Senior Quality Regulatory Engineer

Phone

Get the full picture

Is GeNO your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Check if GeNO has recently received funding, and reach out quickly before it becomes old news!

Website visits: Recent activity has been detected on your website

Product Launch: Get notified when GeNO launches new products

Check out if GeNO is spiking on competitors!

Funding: Get notified immidiatlly once GeNO has new funding data

Earning: See what the market has to say on GeNO recently announced quarterly report

Competitive Alert! Recent activity has been detected by your competitor Masked Content

GeNO, which may be a good buyer, showed buying intent in Masked Content Topic

Click to see if GeNO had a recent Job posting/layoffs

Congratulate Masked Content for being promoted to Masked Content at GeNO

Recommended Actions

Introduce yourself to Masked Content, who has shown a strong intent to purchase lately

Find 2 more new buyers

View Email Formats for GeNO

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

GeNO is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

GeNO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GeNO.

GeNO financials insights

Gather financial insights about GeNO, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2009

Private Equity

$2.1M